Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12287978 | 0.84 | NOS1 (0.45) | ALDH1A1 | |
| SCHEMBL1728940 | 0.84 | NOS1 (0.45) | ALDH1A1 | |
| SCHEMBL14271350 | 0.84 | ALDH1A1 (0.40) | ALDH1A1ELANEPOLBPDE4B | |
| SCHEMBL670165 | 0.80 | POLB (0.43) | POLBLMNA | |
| SCHEMBL5567091 | 0.80 | POLB (0.43) | POLBLMNA | |
| SCHEMBL670164 | 0.80 | POLB (0.43) | POLBLMNA | |
| SCHEMBL15500843 | 0.79 | L3MBTL1 (0.48) | ALDH1A1POLBKMT2ATDP1MAPK1 | |
| SCHEMBL6764374 | 0.77 | SYK (0.41) | POLBKMT2AL3MBTL1 | |
| SCHEMBL6764370 | 0.77 | SYK (0.41) | POLBKMT2AL3MBTL1 | |
| SCHEMBL22798569 | 0.73 | POLB (0.44) | POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | MAVS, HAVCR2, EIF2AK2 | ALDH1A1 4169/4885ELANE 4051/4885POLB 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.